Cancer Biomarkers Market Size, Growth, Report By 2032

The global cancer biomarkers market size is expected to surpass around US$ 34.32 billion by 2032 with a remarkable CAGR of 12.10% from 2023 to 2032.

Rising cancer incidences all over the world are one of the major factors driving the global cancer biomarkers market. Cancer is the leading cause of mortality worldwide, according to the World Health Organization (WHO), with an estimated 10 million deaths projected by 2020, accounting for about one in every six deaths.

Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1637

Lung cancer, breast cancer, rectum cancer, and prostate cancer are the four most common malignancies and because of those illnesses, the creation of cancer biomarkers has become a market requirement. On the other hand, factors such as unregulated government rules and reimbursement requirements, as well as the high cost of medication development, are impeding the worldwide cancer biomarkers market’s growth.

Report Highlights

On the basis of type, breast cancer segment holds the largest market share in the global cancer biomarkers market. The growing prevalence of breast cancer among working women is driving the segment growth over the projected period.
On the basis of biomolecule, genetic biomarkers segment holds the largest market share in the global cancer biomarkers market. The genetic biomarkers are widely employed for the treatment of cancer.
On the basis of application, diagnostics segment holds the largest market share in the global cancer biomarkers market. During the projected period, the factors such as the expanding development of cancer biomarkers based on oncology tests with high efficiency are driving the segment growth.

Regional Snapshot

North America is the largest segment for cancer biomarkers market in terms of region. The U.S. is dominating the cancer biomarkers market in the North America region. In the cancer biomarkers market, North America has a high number of market players. The U.S. government is actively spending in research and development in order to develop new products. Furthermore, the adoption of innovative and advanced technologies is propelling the cancer biomarkers market in the North American region.

Asia-Pacific region is the fastest growing region in the cancer biomarkers market.The increased prevalence of cancer is driving the market for cancer biomarkers in the Asia-Pacific region. Furthermore, the government is constantly sponsoring research and development operations for new items. As a result, increased awareness of cancer biomarkers is fueling market growth in the Asia-Pacific region.

Table of Contents

Cancer Biomarkers Market Scope

Report Coverage	Details
Market Size by 2032	USD 34.32 Billion
Growth Rate from 2023 to 2032	CAGR of 12.10%
Largest Market	North America
Fastest Growing Market	Asia Pacific
Base Year	2022
Forecast Period	2023 to 2032
Segments Covered	Type, Biomolecule, Profiling Technology, End User, Application, Region

Cancer Biomarkers Market Dynamics

Drivers

Growing incidences of cancer

The cases of cancer disease are growing at a rapid pace. The biomarkers are used predominantly for the treatment of cancer. As per statistics provided by World Cancer Research Fund International, in 2018 around 18 million people were suffering from cancer. Moreover, lung cancer and breast cancer are life threatening cancers. As a result, growing incidences of cancer is driving the growth of the global cancer biomarkers market during the forecast period.

Restraints

Lack of reimbursement policies

The government in underdeveloped and developing countries does not provide favorable reimbursement policies. The need for reimbursement policies is growing due to surge in the number of cancer patients. In addition, these nations lack for proper resources for the development of cancer biomarkers. The financial conditions are not favorable in these regions. The developed countries’ government help these countries to develop novel products. In addition, they also fund healthcare sector in these regions. Thus, lack of reimbursement policies is restricting the growth of the global cancer biomarkers market.

Opportunities

Growing technological developments

The technological advancements are helping to develop cancer biomarkers with advanced features. The innovation in technologies is also assisting in finding new ways to ways for dealing with cancer diseases. The latest technologies are addressing new problems that healthcare sector is facing since few years. With the help of innovative technologies, new devices and gadgets are being developed and manufactured that help in the treatment of cancer. Thus, growing technological developments is creating lucrative opportunities for the growth of the global cancer biomarkers market over the forecast period.

Challenges

High cost for treatment and diagnosis

The developing and underdeveloped countries cannot afford for the treatment and diagnosis of cancer. The treatment is very costly as devices used for the cancer treatment are deployed with latest and advanced technologies. This factor adds up to the final cost of treatment and diagnosis. As a result, high cost of treatment and diagnosis is a major challenge for the expansion of the global cancer biomarkers market.

Key Developments

Food and Drug Administration (FDA) approved next generation sequencing based companion diagnostic for EGFR Exon 20 insertion mutant non-small cell lung cancer tumor tissue by Thermo Fisher Scientific in December 2020.
Astra Zeneca and Biocartis Group NV signed a deal in November 2018 with the goal of obtaining faster lung cancer diagnosis findings with biomarkers across Europe. In certain European nations, a prospective lung cancer study using the Idylla EFGR Mutation Test will be done.
F. Hoffmann-La Roche Ltd. released the Elecsys Anti-p53 immunoassay in April 2021 to aid in the diagnosis of various cancer kinds.
Biocept released a liquid biopsy test to detect Target Selector pan to detect TRP proteins in November 2019. With the use of this test, biomarkers in a blood sample can be detected.
Therascreen BRAF test was introduced by Qiagen N.V. in April 2020 as a companion diagnostic to a BRAFTOVI based regimen in metastatic colorectal cancer.

Cancer Biomarkers Market Companies

F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
QIAGEN N.V.
Illumina Inc.
Bio-Rad Laboratories Inc.
Abbott Laboratories
Exact Sciences
Meso Scale Diagnostics LLC
Seegene Technologies Inc.
Siemens Healthineers

Segments Covered in the Report

By Type

Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Liver Cancer
Lung Cancer
Others

By Biomolecule

Genetic Biomarkers
Epigenetic Biomarkers
Metabolic Biomarkers
Proteomic Biomarkers
Others

By Application

Drug Discovery and Development
Diagnostics
Personalized Medicine
Others

By Profiling Technology

Omic Technologies
Imaging Technologies
Immunoassays
Cytogenetics-based Tests

By End User

Hospitals
Academic and Cancer Research Institutes
Ambulatory Surgical Centres
Diagnostic Laboratories

By Geography

North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa